Looking to invest £2,000? Here are 2 pharma stocks I’d buy today

Harvey Jones says these two pharmaceutical stocks have something to please both momentum and contrarian investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The pharmaceutical industry is a tantalising one for investors. It covers the full gamut of stocks, from high-risk, high-reward start-ups, to multi-billion pound blue-chip dividend payers. Yet some of those blue-chips can also be surprisingly volatile. 

Two legs bad, four legs good

Just look at FTSE 100-listed rare disease specialist Shire (LSE: SHP). This is a major UK company, even if it doesn’t have the profile of AstraZeneca or GlaxoSmithKline, with a £30bn market cap. It was a lot higher before, but its share price has crashed from a peak of 5,550p in 2015 to just 3,258p today, a precipitous 41% drop.

That may scare some investors, but others will be tempted. They may consider now a cut-price entry point. If so, they should also look at FTSE 250 stock Dechra Pharmaceuticals (LSE: DPH), which specialises in prescription-only pet medicines and has a much smaller market capitalisation of £2.6bn. Its share price has performed very differently to Shire’s, soaring 53.8% in the past year, and 243% over five years. 

Dechra is up, Shire is down. Which is the better prospect? Or is there a strong case to buy both of them?

Animal magic

Last month Dechra showed its teeth to post a strong set of first-half numbers across its European and US operations, with reported group revenue up 12.5% at actual exchange rates to £194.1m. Revenue growth in North American pharmaceuticals was particularly strong at 20.7%.

Underlying operating profit grew of 22.3% at constant exchange rates while operating margins expanded by 220 basis points to 24.6%. Before these results my Foolish colleague Royston Wild called it a no-brainer pharma stock to buy today, and he called it correctly. 

Momentum play

Dechra is growing through acquisitions, recently bolting on RxVet in New Zealand, and announcing larger acquisitions of AST Farma and Le Vet. My concern is a predictable one: years of soaraway growth have pushed its forward valuation to a hefty 33.4 times earnings. Its PEG stands at a toppy 2.6. However, forecast earnings per share (EPS) growth of 17% in the year to 30 June 2018, then 18% the year after, appears to justify this. Momentum is on its side and soon those acquisitions will be bedding in too.

Contrarian investors may prefer Shire. In January, it posted an impressive 33% jump in full-year revenues but it is the future that counts, and markets were unnerved by warnings that revenue growth is set to weaken. This is mainly due to costs from its new US plasma manufacturing site start-up, as well as growing competition from rival generic treatments and lower royalties. Shire warned of a 3% cut in EPS projections for 2018.

Contrarian buy

Several brokers have downgraded Shire but private investors who take a longer term view, and are willing to sit tight for a few lean years, could benefit as a result. Trading at a forecast valuation of just 8.8 times earnings, Shire’s entry price certainly looks right. GA Chester certainly thinks this is the case, rating it a bargain basement buy. If I had £2,000 to invest, I might split my money evenly between the two of them.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca and Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »